Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CFZ533 in Healthy Subjects and Rheumatoid Arthritis Patients
Conditions
Interventions
CFZ533
Placebo
Locations
6
United States
Novartis Investigative Site
Anniston, Alabama, United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative Site
South Miami, Florida, United States
Novartis Investigative Site
Lincoln, Nebraska, United States
Novartis Investigative Site
Duncansville, Pennsylvania, United States
Novartis Investigative Site
Taipei, Taiwan
Start Date
January 7, 2013
Primary Completion Date
February 3, 2017
Completion Date
February 3, 2017
Last Updated
December 11, 2020
NCT06647069
NCT07484243
NCT06841562
NCT07268326
NCT07233655
NCT07029555
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions